0000000000548053

AUTHOR

Félix Manso

showing 2 related works from this author

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

2020

PETHEMA, HOVON, PALG, GATLA cooperative groups.

MaleMultivariate analysisOverweightTOXICITYBody Mass Index0302 clinical medicineLeukemia Promyelocytic AcuteRecurrenceAcute promyelocytic leukemiaAntineoplastic Combined Chemotherapy ProtocolsDIFFERENTIATION SYNDROMEOutcomeAged 80 and overAIDA protocolMercaptopurineMortality rateIncidence (epidemiology)HematologyGeneral MedicineMiddle AgedPrognosisTreatment OutcomeVincristinePopulation Surveillance030220 oncology & carcinogenesisFemalemedicine.symptomUnderweightAdultmedicine.medical_specialtyAdolescentACUTE MYELOID-LEUKEMIADIAGNOSISYoung Adult03 medical and health sciencesInternal medicinemedicineAsparaginaseHumansObesityRisk factorAgedRESPONSE CRITERIAOVERWEIGHTbusiness.industrynutritional and metabolic diseasesANTHRACYCLINEmedicine.diseaseObesityRISK-ADAPTED TREATMENTMethotrexateTRANS-RETINOIC ACIDPrednisonebusinessBody mass index030215 immunologyEuropean Journal of Haematology
researchProduct

Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemother…

2011

Background Fms-like tyrosine kinase-3 (FLT3) gene mutations are frequent in acute promyelocytic leukemia but their prognostic value is not well established. Design and Methods We evaluated FLT3-internal tandem duplication and FLT3-D835 mutations in patients treated with all-trans retinoic acid and anthracycline-based chemotherapy enrolled in two subsequent trials of the Programa de Estudio y Tratamiento de las Hemopatias Malignas (PETHEMA) and Hemato-Oncologie voor Volwassenen Nederland (HOVON) groups between 1996 and 2005. Results FLT3-internal tandem duplication and FLT3-D835 mutation status was available for 306 (41%) and 213 (29%) patients, respectively. Sixty-eight (22%) and 20 (9%) pa…

MaleAIDA PROTOCOLGene mutationmedicine.disease_causeGastroenterologyLeukemia Promyelocytic AcuteRESIDUAL DISEASEhemic and lymphatic diseasesMOLECULAR SUBTYPESChildanthracyclinesMutationRemission InductionFLT3 mutationshemic and immune systemsHematologyMiddle AgedPrognosisall-trans retinoic acidLeukemiaTreatment Outcomeembryonic structuresFemaleTandem exon duplicationmedicine.drugAcute promyelocytic leukemiaAdultmedicine.medical_specialtyAdolescentAntineoplastic AgentsTretinoinACUTE MYELOID-LEUKEMIABiologyYoung AdultQUALITY-CONTROLTretinoinPOOR-PROGNOSISInternal medicinemedicineCoagulopathyHumansAgedprognostic factorsOriginal Articlesacute promyelocytic leukemiamedicine.diseaseSurvival AnalysisINTERNAL TANDEM DUPLICATIONRISK-ADAPTED TREATMENTPML/RAR-ALPHAfms-Like Tyrosine Kinase 3Fms-Like Tyrosine Kinase 3ImmunologyPETHEMA GROUPMutation
researchProduct